Comparative Pharmacology
Head-to-head clinical analysis: NATAZIA versus NORINYL 1 50 28 DAY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NATAZIA versus NORINYL 1 50 28 DAY.
NATAZIA vs NORINYL 1+50 28-DAY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Estetrol is a selective estrogen receptor modulator (SERM) with mixed agonist/antagonist activity; drospirenone is a spironolactone analog with antimineralocorticoid and antiandrogenic activity. Combined oral contraceptive inhibits ovulation and alters cervical mucus.
Norethindrone and ethinyl estradiol combination works by suppressing gonadotropin-releasing hormone (GnRH) from the hypothalamus, reducing luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion, thereby inhibiting ovulation. Norethindrone also alters cervical mucus viscosity and endometrial lining, impeding sperm penetration and implantation.
Drospirenone 3 mg / ethinyl estradiol 0.03 mg orally once daily for 21 days followed by 7 days of placebo.
One tablet orally once daily for 28 days, with 7 inactive tablets during the last 7 days. Each active tablet contains norethindrone 1 mg and ethinyl estradiol 50 mcg.
None Documented
None Documented
Terminal half-life approximately 30 hours for drospirenone and 24 hours for ethinyl estradiol; steady-state achieved within 8–10 days.
Norethindrone: ~8-11 hours; Mestranol: 24 hours (prodrug, ethinyl estradiol half-life ~13-27 hours).
Fecal excretion is the primary route (approximately 68%), with renal excretion accounting for about 27% (mostly as metabolites).
Renal: ~40% as metabolites; Biliary/Fecal: ~60% as metabolites.
Category C
Category C
Oral Contraceptive
Oral Contraceptive